Fecal Microbial DNA Analysis for Non-Invasive Cancer Monitoring

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for monitoring the effects of anti-cancer drugs are invasive, time-consuming, and costly, requiring large cohorts and prolonged follow-ups, and do not provide efficient or accurate non-invasive means to detect therapeutic effects.

Innovation Solution

A non-invasive method involving the analysis of fecal microbial genomic DNA using fingerprint spectrum analysis, partial least squares-discriminate analysis, and quantitative real-time PCR to identify key microorganisms associated with anti-cancer agent effects, allowing for the monitoring of changes in gut flora composition.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If epidemiological studies with large cohorts and prolonged follow-ups are used to evaluate cancer chemoprevention strategies, then the accuracy and reliability of monitoring therapeutic effects is improved, but the time consumption and cost increase significantly

Engineering Contradiction:

Improveaccuracy of monitoring therapeutic effectsVSAvoidtime consumption

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent extracts and monitors specific indicator microorganisms (such as Bacteroides vulgatus) from the complex gut flora as biomarkers for cancer chemoprevention effects. By focusing on these specific microbial indicators rather than conducting long-term epidemiological studies, the method achieves reliable monitoring of therapeutic effects without requiring prolonged follow-up periods of 10-20 years

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses gut flora composition changes as an intermediary indicator to reflect the therapeutic effects of cancer chemoprevention agents. Instead of directly measuring cancer incidence over long periods, the method monitors changes in microbial composition (particularly indicator microorganisms) that correlate with therapeutic outcomes, providing a time-efficient proxy measurement

Inventive Principle:

Principle #24Intermediary (Mediator)

2Measurement precision

If traditional invasive methods involving euthanasia and methylene blue staining are used to determine ACF numbers, then the measurement precision of cancer risk assessment is improved, but the ease of operation and animal welfare deteriorate

Engineering Contradiction:

Improveprecision of ACF determinationVSAvoidinvasiveness of procedure

Core Design Contradiction:

Measurement precisionVSEase of operation

Solution Approach 1:

The patent replaces the mechanical invasive procedure of euthanasia, dissection, and methylene blue staining with a molecular biology approach using DNA extraction and fingerprint spectrum analysis from fecal samples. This substitution maintains the ability to assess cancer risk (through ACF-related microbial changes) while eliminating the need for invasive animal killing and tissue staining

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent uses fecal microbial DNA as an intermediary to assess colorectal cancer risk and monitor chemoprevention effects. Instead of directly counting ACF through invasive staining, the method analyzes microbial composition in feces that reflects ACF development, providing a non-invasive proxy measurement

Inventive Principle:

Principle #24Intermediary (Mediator)

3Ease of operation

If culture-based methods are used to analyze fecal flora, then the ease of operation is improved, but the measurement precision deteriorates due to selective growth conditions altering microbial composition

Engineering Contradiction:

Improvesimplicity of culture methodVSAvoidaccuracy of microbial composition

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The patent replaces culture-based methods with molecular fingerprint spectrum analysis of total microbial genomic DNA extracted directly from fecal samples. This substitution eliminates the selective bias introduced by culture conditions that prevent certain microbes from growing, thereby accurately reflecting the true microbial composition including fastidious organisms that cannot be cultured

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes the detection parameter from observable colony growth (culture method) to DNA sequence fingerprinting (molecular method). By analyzing the V3 regions of 16S rDNA gene sequences, the method detects microbial composition based on genetic markers rather than growth characteristics, ensuring all microbes are detected regardless of their culturability

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS8097417B2Methods for detecting therapeutic effects of anti-cancer drugs by monitoring changes in gut flora

Publication Date: 2012.01.17 PERFECT CHINA

AI summary

Non-invasive methods for monitoring the effect of an agent for treating colorectal cancer, comprising (1) collecting fecal samples from healthy subjects, subjects having precancerous lesions, and subject having precancerous lesions and being treated with an anti-cancer agent; (2) isolating total microbial genomic DNA from the fecal samples to provide total microbial genomic DNA; (3) comparing the total microbial genomic DNA using fingerprint spectrum analysis; (4) identifying key fingerprint bands correlated with the effect of the anti-cancer agent; (5) identifying key microorganisms associated with the key fingerprint bands; (6) designing microbial sequence-specific primers and probes; and (7) determining the quantitative differences of the key microorganisms in fecal samples to identify an indicator microorganism for monitoring the effect of the anti-cancer agent.